To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
Status:
Completed
Trial end date:
2021-10-08
Target enrollment:
Participant gender:
Summary
This open-label, multi-centre phase IIIb study will assess the effectiveness, benefits and
potential harms in the use of olaparib monotherapy treatment for patients with HER2-ve
metastatic breast cancer associated with germline or somatic breast cancer susceptibility
gene (gBRCA1/2 or sBRCA1/2) mutations.